World Sleep Industry ENCYCLOPEDIA

Sleep Metabolome Research Services

6.5.3

Definition, scope, and evidence boundary

Sleep metabolome research services examine small-molecule variation associated with sleep, wakefulness, and circadian timing through study design, specimen and metadata management, analytical measurement, data processing, statistical interpretation, and reporting. Matrices may include plasma, serum, urine, saliva, breath, cerebrospinal fluid, tissue, or another approved specimen type. Mass spectrometry, nuclear magnetic resonance, or complementary platforms may be aligned with sleep diaries, actigraphy, polysomnography, and clinical information. A metabolome is a dynamic snapshot shaped by physiology, behavior, environment, and technology, not a fixed personal “health fingerprint.”

A project should distinguish untargeted discovery, targeted confirmation, absolute or relative quantification, stable-isotope tracing, biomarker development, and mechanistic research and state whether the provider receives data only or manages sampling through analysis. An exploratory feature, a database candidate, and a metabolite confirmed with an authentic standard have different evidentiary strength. Association alone cannot show that a sleep problem was caused by one metabolic pathway and does not constitute a diagnosis or advice about medicines, supplements, diet, or product efficacy. Quantitative methods used for regulatory decisions also require the validation expected for their jurisdiction and intended use.

Research question, sleep phenotype, and timing

The protocol should prespecify the population or model, sleep exposure and outcome, comparator, matrix and sampling times, primary measure, estimand, and validation stage. Insomnia symptoms, sleep duration, stages, fragmentation, respiratory events, sleep deprivation, and circadian misalignment are different constructs. Self-report, diaries, actigraphy, home testing, and polysomnography should not be pooled without labels. Sample size should reflect interpersonal variation, repeated measures, expected effects, batch, missingness, and multiplicity rather than the number of peaks a platform may detect.

Many metabolites vary with clock time and sleep–wake, feeding–fasting, and activity cycles. Records should capture local time, time zone, phase relative to sleep onset or awakening, recent sleep, light, posture, activity, meals and fluids, caffeine, alcohol, smoking, medicines, menstruation or pregnancy, shift work, comorbidity, and acute stress. Distinguishing endogenous circadian effects from sleep and behavior generally requires a controlled design with repeated, sufficiently time-resolved sampling. One morning specimen can support a comparison within its collection window, not a full claim about a daily rhythm.

Collection, preanalytics, and batch design

The sampling plan should lock matrix, container or anticoagulant, volume, serum clotting, centrifugation, aliquoting, processing delay and temperature, stabilization, transport, storage, and freeze–thaw count. Hemolysis, lipemia, residual cells, microbial activity, evaporation, and contamination can alter a profile. Urine requires a defined collection interval and dilution strategy, while saliva and breath require control of the device and oral, flow, or environmental conditions. Identity conflicts, excessive delay, temperature excursions, insufficient volume, and visible abnormalities should follow predefined acceptance and quarantine rules.

Cases, controls, time points, and intervention orders should be randomized or balanced across extraction, injection, and instrument batches. Paired samples or specimens from one participant may be kept adjacent or placed in a design that permits drift estimation. Each batch may include system-suitability samples, process and solvent blanks, pooled quality-control samples, internal standards, replicates, and suitable reference materials, with insertion frequency, acceptance metrics, control limits, and investigation and reanalysis rules defined in advance. A passing control shows only that the monitored process performed within its limits; it cannot erase sampling bias or error in unmonitored analytes.

Analytical platforms and measurement strategy

Liquid chromatography–mass spectrometry can cover many polar and lipid molecules. Gas chromatography–mass spectrometry often uses derivatization and suits volatile or volatilizable compounds. Nuclear magnetic resonance offers nondestructive measurement, structural information, and repeatability but differs in sensitivity and coverage. Ion mode, chromatography, extraction solvent, and platform each select a portion of the metabolome, so no single method provides complete coverage. Selection should follow the question, matrix, analyte properties, required quantification, sample volume, and validation needs, with instruments, columns, reagents, lots, sequences, and critical settings recorded.

Untargeted analysis captures signals broadly to generate hypotheses, and its first output is often a feature defined by mass-to-charge ratio, retention time, and intensity. Targeted analysis addresses prespecified analytes in an applicable matrix and develops evidence for calibration, internal standards, selectivity, precision, accuracy, sensitivity, stability, matrix effects, and dilution. Neither approach is superior merely because it yields more peaks. Exploratory work may use fit-for-purpose confirmation, but results supporting clinical trials, medicines, or other regulatory decisions require a separate determination of full validation and incurred-sample reanalysis obligations.

Data processing, identification, and quality control

The workflow should retain raw files and checksums and document feature detection, deconvolution, alignment, integration, isotope and adduct grouping, blank subtraction, drift assessment, batch correction, missing-value handling, and filtering. Parameters, software, databases, spectral-library versions, code, and computing environments should be frozen or versioned. Excessive smoothing, peak filling, or batch correction may erase a real phase or group signal. Manual reintegration and sample exclusion require an audit trail, and rules should not change silently after unblinding or viewing group labels.

Accurate mass or one database match usually supports a candidate annotation, not identification of every feature as a metabolite. Reports should state the identification or annotation level and supporting evidence, such as retention time, fragmentation spectrum, isotope pattern, an orthogonal technique, and a same-run authentic standard, while addressing isomers and compounds absent from libraries. Pooled-control reproducibility, blank background, internal-standard response, retention time, mass accuracy, peak shape, carryover, and signal drift should be reviewed together. A failing batch cannot be silently repaired by deleting inconvenient specimens.

Statistics, multi-omics, and interpretation

The statistical plan should state the analysis unit, normalization basis, transformation and scaling, treatment of values below detection or quantification ranges, missingness, outliers, covariates, and multiplicity. Unsupervised displays such as principal-component plots can reveal structure and anomalies but do not validate a group difference. Supervised models must prevent leakage of participants, batches, or preprocessing information across training and test data and report tuning, internal validation, independent validation, calibration, and failure behavior. Effect sizes and uncertainty are more informative than a list of significant values alone.

A metabolite may originate from the host, diet, medicine, microbes, or specimen handling, and the same concentration change can have several explanations. Pathway enrichment depends on annotation quality, the background set, and the database; correlated signals do not by themselves show pathway activation or a causal mechanism. Integration with genomics, transcriptomics, proteomics, microbiomics, and sleep physiology should align participant, specimen, matrix, and time keys and handle scale, batch, and missingness within each layer. Targeted measurements, independent cohorts, or experiments are needed to validate each link in a proposed mechanism.

Delivery, governance, and continuous quality

The delivery package may contain the protocol, specimen and covariate dictionaries, chain records, batch and injection tables, raw-data inventory, feature and metabolite tables, identification evidence, quality-control report, statistical code, software environment, figures, and report. It should distinguish prespecified from exploratory results, relative from absolute quantification, features from identified metabolites, and technical from biological replicates, while disclosing exclusions, failures, batches, missingness, null findings, and limitations. Repository submissions should include study design, specimen preparation, chromatography, mass-spectrometry or NMR methods, and raw and processed data in the required format.

Specimen and data governance should address consent, ethics, coding, access, transfer, retention, cross-border movement, secondary use, and destruction; removing names does not eliminate reidentification risk. The quality system should manage training, instrument maintenance, calibration, reagents and standards, storage temperature, deviations, review, backup, suppliers, and change control. Comparability should be assessed after changes to a platform, method, software, library, or database, and reanalysis should preserve versions rather than overwrite prior results. Quality is shown by a question-fit design, controlled preanalytics, traceable evidence, and restrained conclusions—not by the largest feature count or highest model accuracy.